As a global leader in the field of Inhalation, DFE Pharma offers the pharmaceutical industry the optimal solution for the development of their Dry Powder Inhaler (DPI) drug products. We have been a partner for companies developing drugs for pulmonary delivery for many years. Through these collaborations, we have gained a deep understanding of the market, enabling us to offer a wide range of specialty inhalation grades of lactose and the option to customize to fit any formulation requirement.

Our involvement in inhalation science continues to evolve. Building on our pioneering work in inhalation-grade lactose, we are extending our expertise to areas shaping the next phase of inhaled therapies. This includes supporting the development of inhaled biologics, enabling carrier-free formulations, and strengthening analytical and formulation capabilities. In a field where DPI development is inherently complex, with generics demanding deeper technical know-how and biologics introducing new challenges, DFE Pharma provides the support and expertise to advance product development effectively.

Hence, in addition to our broad excipient portfolio, we offer development-oriented formulation support through specialized services as C2F (Closer to the Formulator) and INTO (our Inhalation Together alliance), accelerating development and reducing time to market.